Journal profile · Biochemistry & Molecular Biology
Molecular Medicine
ISSN 1076-1551 · eISSN 1528-3658 · BioMed Central · UNITED STATES · Bimonthly · Founded 1994
Molecular Medicine: CAS Zone 2 · Medicine (2025 upgraded edition, Top journal); impact factor 8.34; fully open access; APC about USD 3,290; median 98 days to acceptance (115 articles, last 24 months); community-reported acceptance: about 50%; 362 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Molecular Medicine is published by BioMed Central and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Legal and Regulatory Analysis, Linguistic, Cultural, and Literary Studies and Military Technology and Strategies, together about 29% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Molecular Medicine is an open access journal publishing recent findings that elucidate disease pathogenesis at the molecular or physiological level, which may lead to the design of specific tools for disease diagnosis, treatment, or prevention. Manuscripts containing material relevant to the genetic, molecular, or cellular basis of key physiologic or disease processes are considered for publication. Manuscripts submitted to Molecular Medicine should describe the implications of the results for human disease and medicine, at a level approachable by our broad audience. Criteria to consider for studies involving lnc-RNAs or micro-RNAs:
· As lncRNAs and miRNAs have multiple targets, claims of their function mediated by a single target or pathway will not be accepted, unless multiple additional targets are investigated to support functional specificity.
· The rationale to investigate a specific lncRNA or miRNA needs to be specified upfront in the introduction and justified in the context of other miRNAs known to be functional in that specific field.
· The proposed function of the lnc-RNA or miRNA should be validated by gain and loss of function studies.
· Primary cells should be used whenever possible to confirm findings in cell lines.
· In depth investigation in the signaling pathway(s) regulated by the RNA species should be conducted.
· Insight into the regulation of the RNA species and how it relates to the pathologic state should be provided.
· If applicable: Details of initial screen used to identify RNA species involvement in pathway/disease (number of subjects, statistical tests employed, percent change from controls).
From the journal's Aims & Scope
Research area (LetPub): Biochemistry & Molecular Biology
Editor-in-chief Betty DiamondPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Legal and Regulatory AnalysisSocial Sciences9.7%
- Linguistic, Cultural, and Literary StudiesSocial Sciences9.7%
- Military Technology and StrategiesEngineering9.7%
- Immune Response and InflammationImmunology and Microbiology6.2%
- Advanced Glycation End Products researchBiochemistry, Genetics and Molecular Biology4.5%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology3.8%
- Immune cells in cancerImmunology and Microbiology3.7%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology3.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Biochemistry & Molecular Biology | Zone 2 |
| Minor | Cell Biology | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Biochemistry & Molecular Biology | Zone 2 |
| Minor | Cell Biology | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Biochemistry & Molecular Biology | Zone 2 |
| Minor | Cell Biology | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASCurrent ContentsPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 8.34LetPub ·
- Impact factor (publisher) 2025
- 8.3Publisher website ·
- 5-year impact factor (publisher) 2025
- 7.6Publisher website ·
- CiteScore 2026-06
- 9.7LetPub ·
- SJR 2026-06
- 2.07LetPub ·
- SNIP 2026-06
- 1.39LetPub ·
- h-index
- 110LetPub ·
- h-index
- 157OpenAlex ·
- i10-index
- 2,376OpenAlex ·
- 2-year mean citedness
- 8.15OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 343LetPub ·
- Articles per year (publisher)
- 2,023Publisher website ·
- Downloads per year (publisher) 2025
- 2,700,000Publisher website ·
Articles by year OpenAlex count · 3,758 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 236 | 236 | 57 |
| 2025 | 362 | 362 | 2,568 |
| 2024 | 284 | 284 | 4,567 |
| 2023 | 213 | 213 | 4,381 |
| 2022 | 165 | 165 | 4,811 |
| 2021 | 162 | 162 | 5,605 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
98 daysMedian, submission to acceptance · P25–P75 70 days – 164 days
- Acceptance to online
- median 13 days (115 articles)
- Submission to online
- median 119 days
- Sample
- 115 articles with submission and acceptance dates (719 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1 monthLetPub ·
- Average acceptance (community reports)
- 50%LetPub ·
- Submission to first decision
- 2 daysPublisher website ·
- Submission to publication (journal-reported)
- about 8 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 2,790 / USD 3,290 / GBP 2,490 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 3,190 / EUR 2,690 / GBP 2,390 | — | — | |
| LetPub | GBP 2,390 / USD 3,190 / EUR 2,690 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers2, by deadline
Publisher websiteExcerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BioMed Central
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1994
- ISSN
- 1076-1551
- Electronic ISSN
- 1528-3658
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Molecular Medicine
What CAS zone is Molecular Medicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Molecular Medicine is in Zone 2 of Medicine, and in Zone 2 of the minor category Biochemistry & Molecular Biology / Cell Biology / Medicine, Research & Experimental; it is a Top journal. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Molecular Medicine?
The latest impact factor listed by LetPub is 8.34; CiteScore 9.7, h-index 157.
How long does peer review take at Molecular Medicine?
Based on the dates recorded on 115 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 98 days (interquartile range 70–164 days); authors report an average review time of about 1 month; the community-reported acceptance is “about 50%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Molecular Medicine?
According to LetPub and DOAJ records, Molecular Medicine is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, Embase, CAS and Current Contents; that list has not been checked against each database.
Is Molecular Medicine open access, and what is the APC?
Molecular Medicine is a fully open-access journal. APC about USD 3,290.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .